Perrigo Company plc (NYSE:PRGO) Shares Sold by Creative Planning

Creative Planning lowered its stake in shares of Perrigo Company plc (NYSE:PRGO) by 28.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,816 shares of the company’s stock after selling 7,162 shares during the period. Creative Planning’s holdings in Perrigo were worth $458,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Diamond Hill Capital Management Inc. boosted its stake in shares of Perrigo by 83.2% in the second quarter. Diamond Hill Capital Management Inc. now owns 1,940,067 shares of the company’s stock valued at $49,821,000 after purchasing an additional 881,191 shares during the period. AQR Capital Management LLC boosted its stake in Perrigo by 675.5% during the 2nd quarter. AQR Capital Management LLC now owns 970,637 shares of the company’s stock valued at $24,926,000 after acquiring an additional 845,470 shares during the last quarter. National Bank of Canada FI bought a new position in Perrigo during the 1st quarter valued at $19,040,000. Perpetual Ltd boosted its stake in Perrigo by 20.5% during the 1st quarter. Perpetual Ltd now owns 2,780,984 shares of the company’s stock valued at $87,490,000 after acquiring an additional 472,245 shares during the last quarter. Finally, Deprince Race & Zollo Inc. boosted its stake in Perrigo by 11.2% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,882,438 shares of the company’s stock valued at $99,701,000 after acquiring an additional 391,646 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Insider Activity

In other Perrigo news, Director Katherine C. Doyle sold 8,954 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $27.30, for a total value of $244,444.20. Following the completion of the transaction, the director now owns 6,009 shares of the company’s stock, valued at $164,045.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Svend Andersen sold 28,300 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $27.75, for a total transaction of $785,325.00. Following the sale, the executive vice president now directly owns 73,553 shares in the company, valued at approximately $2,041,095.75. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Katherine C. Doyle sold 8,954 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the sale, the director now owns 6,009 shares in the company, valued at approximately $164,045.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,254 shares of company stock worth $1,411,969. 0.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PRGO. Jefferies Financial Group restated a “hold” rating and issued a $30.00 price target (down from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Piper Sandler dropped their price objective on shares of Perrigo from $36.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Perrigo in a report on Monday, September 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Perrigo Stock Up 0.5 %

Shares of PRGO stock opened at $24.31 on Wednesday. The stock has a market cap of $3.31 billion, a P/E ratio of -347.29 and a beta of 0.48. Perrigo Company plc has a one year low of $23.89 and a one year high of $34.60. The stock has a fifty day moving average price of $26.98 and a 200 day moving average price of $28.11. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.99 and a quick ratio of 1.24.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company posted $0.63 earnings per share. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. Analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 17th. Stockholders of record on Friday, August 30th were given a dividend of $0.276 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $1.10 dividend on an annualized basis and a dividend yield of 4.54%. Perrigo’s payout ratio is -1,571.43%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.